Canadian Agency for Drugs and Technologies in Health

Recent papers from Canadian Agency for Drugs and Technologies in Health

1. Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysisCochrane library · 2026
2. Evaluating automated or artificial intelligence search tools for evidence synthesisJournal of the Medical Library Association JMLA · 2026
3. Impact of risk mitigation measures on oral fluoroquinolone prescribing: a multi-site population-based Canadian cohort studyArchives of Public Health · 2026
4. Opioid Agonist Treatment Dispensing Trends Between 2018 and 2022 Across Six Canadian ProvincesCanadian Journal of Physiology and Pharmacology · 2026
5. Medical Radiation Exposures in Canada: 2017Health Physics · 2026
6. Measuring and valuing patient and caregiver productivity costs: a scoping review protocolBMJ Open · 2025
7. Responsible Integration of Artificial Intelligence in Rapid Reviews: A Position Statement From the Cochrane Rapid Reviews Methods GroupCochrane Evidence Synthesis and Methods · 2025
8. Women’s Cardiovascular Health and Cardiac Rehabilitation: a Priority-setting PartnershipCJC Open · 2025
9. Improving the Reporting on Health Equity in Observational Research (STROBE-Equity)JAMA Network Open · 2025
10. Improving the reporting on health equity in observational research (STROBE-Equity): extension checklist and elaborationBMJ · 2025
11. Drug treatments for mild or moderate covid-19: systematic review and network meta-analysisBMJ · 2025
12. Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaborationBMJ Open · 2025
13. Update to the PRISMA guidelines for network meta-analyses and scoping reviews and development of guidelines for rapid reviews: a scoping review protocolJBI Evidence Synthesis · 2025
14. Actions for stakeholders to develop better real-world evidence for HTA bodies/payers decision makingInternational Journal of Technology Assessment in Health Care · 2025
15. Recommendations on the Use of Structured Expert Elicitation Protocols for Healthcare Decision Making: A Good Practices Report of an ISPOR Task ForceValue in Health · 2024
16. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summaryBlood Advances · 2024
17. Development of a Canadian Guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision-makingJournal of Clinical Epidemiology · 2024
18. Consumer engagement in living evidence “a beautiful opportunity”: International qualitative study with patients and methodologistsDeleted Journal · 2024
19. Treatment outcomes of standardized injectable shorter regimen for multi-drugs resistant tuberculosis in Ethiopia: a retrospective cohort studyBMC Infectious Diseases · 2024
20. Preprint Pointers From a Long COVID Scoping Review: Considerations for Source Selection and SearchingJournal of the Canadian Health Libraries Association / Journal de l Association de bilbiothèques de la santé du Canada · 2024